This is a news story, published by CNBC, that relates primarily to Novo Nordisk news.
For more Novo Nordisk news, you can click here:
more Novo Nordisk newsFor more drug discoveries news, you can click here:
more drug discoveries newsFor more news from CNBC, you can click here:
more news from CNBCOtherweb, Inc is a public benefit corporation, dedicated to improving the quality of news people consume. We are non-partisan, junk-free, and ad-free. We use artificial intelligence (AI) to remove junk from your news feed, and allow you to select the best health news, business news, entertainment news, and much more. If you like drug discoveries news, you might also like this article about
Novo Nordisk. We are dedicated to bringing you the highest-quality news, junk-free and ad-free, about your favorite topics. Please come every day to read the latest FDA news, Semaglutide products news, drug discoveries news, and other high-quality news about any topic that interests you. We are working hard to create the best news aggregator on the web, and to put you in control of your news feed - whether you choose to read the latest news through our website, our news app, or our daily newsletter - all free!
effective semaglutide productsCNBC
•
79% Informative
The FDA still has to make a final decision on whether to bar those unapproved versions of semaglutide.
The active ingredient in Wegovy and Ozempic has been in intermittent shortages over the past two years .
Novo Nordisk has filed 50 lawsuits against several clinics, compounding pharmacies and other manufacturers over the last year .
VR Score
70
Informative language
64
Neutral language
53
Article tone
formal
Language
English
Language complexity
69
Offensive language
not offensive
Hate speech
not hateful
Attention-grabbing headline
not detected
Known propaganda techniques
not detected
Time-value
short-lived
External references
5
Source diversity
3
Affiliate links
no affiliate links